Tilray is the first GMP-certified medical cannabis producer to supply cannabis extract products to thousands of patients, physicians, pharmacies, hospitals, governments and researchers on four continents. Tilray Australia and New Zealand is dedicated to supporting healthcare professionals and patients in the region with access to our medicinal cannabis products. We supply our products to government and hospital clients as well as to leading pharmacies across Australia. About Tilray Medical Australia & New Zealand Tilray Medical ANZ was established in 2016 and began providing hospitals Australia-wide with Tilray Purified CBD 100 (non-detect THC) for Paediatric Epilepsy patients, continuing to the present day. In Australia, Tilray provides the Tilray Medical brand of Medicinal Cannabis products plus three additional internationally respected brands, Broken Coast, Redecan and Good Supply, to address the needs of different medicinal cannabis patients. The Tilray Medical brand maintains an ethical medical reputation by delivering pharmaceutical quality, consistency, and purity that Healthcare Professionals trust. All manufacturing stages of Tilray Medical finished products (including raw material cultivation) are carried out with Quality Control in full compliance with the European Union Code of Good Manufacturing Practice and TGA Therapeutic Goods Order TGO93 requirements. About Tilray Medical Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments in 20 countries and across five continents, with a comprehensive portfolio of THC and CBD products used by over 70,000 patients worldwide. Tilray has supported medical trials globally, across Europe, Canada, the United States, Australia, and Latin America, studying the efficacy of medical cannabis as a treatment for indications including pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, post-traumatic stress disorder, and alcohol use disorders.